The amount of medical text data is increasing dramatically. Medical text data record the
progress of medicine and imply a large amount of medical knowledge. As a natural …

Heart failure (HF) treatment has changed substantially over the last 30 years, leading to
significant reductions in mortality and hospital admissions in patients with HF with reduced …

Background Data regarding using angiotensin receptor-neprilysin inhibitor (ARNI) in
patients with both heartfailure with reduced ejection fraction (HFrEF) and advanced chronic …

Background The effectiveness and safety of initiating sacubitril/valsartan therapy among
patients who are hospitalized for acute heart failure (HF) is unclear. Methods A cohort of …

Aims To assess the effect of angiotensin receptor blockers/neprilysin inhibitors (ARNI) on left
ventricular (LV) ejection fraction (LVEF) and LV dimensions in a real‐life cohort of heart …

Background Controversy has persisted over the clinical benefits of low‐dose
sacubitril/valsartan in patients with heart failure (HF). Hypothesis Low‐dose …

Background Treatment of heart failure with reduced ejection fraction (HFrEF) has been
revolutionized by angiotensin receptor/neprilysin inhibitor (ARNI). ARNI has been shown to …

Background The VICTORIA trial demonstrated a significant decrease in cardiovascular
events through vericiguat therapy. This study aimed to assess the potential mechanisms …

Background: Sacubitril/valsartan, an angiotensin receptor–neprilysin inhibitor (ARNI), has
demonstrated a survival benefit and reduces heart failure hospitalization in patients with …

—WH Auden (1) The discovery of the cardiovascular protective effects of sodium-glucose
cotransporter inhibitor (SGLTi) drugs was an outcome of the US Food and Drug …